1.Progress of single-cell sequencing in multiple myeloma
Journal of Leukemia & Lymphoma 2021;30(4):250-253
Multiple myeloma (MM) is a malignant hematological disorder caused by the abnormal proliferation of monoclonal plasma cells. Traditional high-throughput cell sequencing reflects the heterogeneity of cell population, while it ignores the genetic information in single-cell. The development of single-cell sequencing has enabled the access to cell-to-cell variation in tumor and microenvironment of bone marrow, providing a deep understanding of the pathogenic mechanisms of MM and guidance for clinical treatment. This paper reviews the latest progress of single-cell sequencing and its application in disease pathogenesis, monitoring of disease progression, immunotherapy and therapeutic responses of MM.
2.Protective Effect of Fuzheng Chuyi Granules on the Mice Infected with Influenza Virus
Xiaoyan GONG ; Xiaobo QU ; Zeyu WANG
Traditional Chinese Drug Research & Clinical Pharmacology 1993;0(03):-
Objective To observe the influence of Fuzheng Chuyi Granules on the mice infected with influenza virus and to observe its antibiotic and antivirus actions in vitro.Methods The death rate of mice infected with influenza virus in each group was compared and antimicrobial activity of Fuzheng Chuyi Granules was observed in vitro.Hep-2 passage cells were subcultured to observe the protective effect of the maximal non-toxic dosage(TD0),the infective dose of 50% tissue culture(TCID50) and other different dosage of Fuzheng Chuyi Granules on cells infected virus.Results Compared with that in negative control group,the death rate of infected mice was lower in Fuzheng Chuyi Granules groups.Fuzheng Chuyi Granules had antibiotic action on bacteria in vitro,particularly on streptococcus pneumoniae.Meanwhile,Fuzheng Chuyi Granules could alleviate cytopathy induced by virus.Conclusion Fuzheng Chuyi Granules have a certain protective effect on the animal infected with virus,and also have antibiotic and antivirus actions.
3.Development of semi-conductor laser therapeutic apparatus
Xiaoyan YANG ; Jiqing YANG ; Xuemin QU
Chinese Medical Equipment Journal 2003;0(12):-
Low-power laser irradiation has an excellent effect when applied clinically. But existing laser apparatuses have many disadvantages such as inconvenience. So, this paper develops an intelligent semi-conductor laser therapeutic apparatus and introduces its hardware structure and software design as well as its test and clinical application.
4.BRAF and targeted treatment for non-small cell lung cancer
Xiaoyan KANG ; Liyan QU ; Xia SONG
Journal of International Oncology 2016;43(8):625-627
B-Raf kinase (BRAF) gene is a driver mutation,and is an effective target in the treatment of non-small cell lung cancer (NSCLC).Studies have shown that BRAF inhibitors are effective for treatment of NSCLC with BRAF mutant.It is important to understand the clinicopathologic features and the research progress of BRAF inhibitors for the individual treatment of NSCLC.
5.Action Mechanism of Rukang Oral Liquid in Rats with Hyperplasia of Mammary Glands
Xiaoyan WU ; Falin QU ; Li XU
China Pharmacist 2016;19(4):647-651
Objective:To study the action mechanism of Rukang oral liquid in rats with hyperplasia of mammary glands. Meth-ods:The rats were randomly divided into six groups:the normal group, the model group, tamoxifen group, low, medium and high dose of Rukang oral liquid groups. The model of hyperplasia of mammary glands was induced by estradiol benzoate injection and progester-one injection. After the administration, ELISA was used to detect the serum concentrations of ER, PR, P53 and Oct4, Western blot was used to detect the expression of ER, PR, P53 and Oct4 in breast tissue, a fluorescence quantitative PCR method was used to de-tect the expression of GnRH, GnRHR, and the expression of telomerase in breast tissue was detected by in situ hybridization. Results:Rukang oral liquid could reduce the expression of ER and PR in serum and breast tissue(P<0. 01), reduce the expression of P53, te-lomerase and Oct4(P<0. 01), and decrease the expression of GnRH in hypothalamus and pituitary, which could reverse the hyperpla-sia of mammary glands and played the role effectively(P<0. 01). Conclusion: Rukang oral Liquid can reduce the expression of ER and PR in serum and breast tissue, and decrease the expression of GnRH in hypothalamus and pituitary to play the role in the treatment of hyperplasia of mammary glands. Rukang oral Liquid may prevent breast hyperplasia from developing into breast cancer through re-ducing the expression of three related markers P53, telomerase and Oct4.
6.Report on recent progress of multiple myeloma in the 53rd annual meeting of American Society of Hematology
Min ZHAO ; Xiaoyan QU ; Lijuan CHEN
Journal of Leukemia & Lymphoma 2012;21(1):10-12
The 53rd ASH meeting was held in San Diego in December 2011. The meeting has received many advanced reports on the diagnosis and treatment of multiple myeloma (MM).On therapy,with the application of thalidomide, lenalidomide and bortezomib as inductive treatments, the clinical outcomeshave been improved greatly in MM patients.Pomalidomide,a new immunomodulator,can be hopefully used as a frontline medicine for MM because of its high response. Bendamustine combination with other treatments induced efficient response and good response rates in MM patients with renal insufficiency or relapsed/refactory disease. Currently autologous stem cell transplantation is still the standard care for newly diagnosed young MM patients.At this time other kinds of novel agents have entered into clinical trials and have shown a bright future of application.
7.Appliation of the combination of antiangiogenic agents and EGFR-TKIs in advanced NSCLC treatment
Liyan QU ; Xiaoyan KANG ; Xia SONG
Journal of International Oncology 2017;44(1):57-59
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)and anti-angio-genic drugs have individually demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Recent studies demonstrate that the combination of anti-EGFR and anti-angiogene-sis can more significantly enhance clinical benefit,and even can remit EGFR-TKIs resistance in the treatment of advanced NSCLC.According to the different kinds of anti-angiogenesis drugs,recent clinical studies mainly include the combination of anti-vascular endothelial growth factor monoclonal antibody bevacizumab plus EGFR-TKIs and multi-targeted receptor anti-angiogenic tyrosine kinase inhibitor plus EGFR-TKIs,and the for-mer results show a more significant improvement in terms of safety and efficacy in the treatment of advanced NSCLC.Therefore,the combination of bevacizumab plus EGFR-TKIs can be used as a new treatment standard in the treatment of some patients with NSCLC.
8.The Relationship between Adolescent Personality Traits and Parental Rearing
Xiaoyan QU ; Yiqun GAN ; Xiuqiong SHEN
Chinese Journal of Clinical Psychology 2001;0(03):-
Objective: To explore the possible relationships of adolescent personality traits, personality deviation and parental rearing pattern. Methods: 393 students from a high school in ShanDong were tested by PACL and EMBU. Re- sults: Generally, adolescent personality traits showed different profiles while factors of EMBU varied in different levels; Antisocial personality deviation was greatly influenced by parental warmth and understanding factor, father's punishment and rigor, father's overprotection. Schizoid personality deviation was mainly influenced by parental warmth and under- standing. Passive- aggressive personality dysfunction was influenced by father's warmth and understanding. Conclusion: Adolescent personality deviation is greatly influenced by parental rearing.
9.Advances in the treatment of non-small cell lung cancer: focus on anti-PD-1/PD-L1 antibody
Changcheng ZHANG ; Xiaoyan KANG ; Liyan QU ; Xia SONG
Journal of Chinese Physician 2017;19(8):1275-1278
Immunotherapy is revolutionizing the treatment of non-small cell lung cancer (NSCLC).Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) monoclonal antibodies have recently led to significant and durable improvements in the clinical outcome of NSCLC,and the anti-PD-1 antibody has been approved to use in first-line and second-line treatment of NSCLC.However,there are still many problems to be solved.The role of PD-L1 as a predictive biomarker remains unclear.Combination treatment models are being explored.This review summarizes the clinical efficacy,drug adverse reaction,combined treatment,and potential immune biomarkers of anti-PD-1/PD-L1 antibody research progress in the treatment of NSCLC.
10.Analysis of the examination results of clinical skill strengthening training before practice in Hospital
Yinxia WU ; Yanshu LI ; Qiuhong QU ; Xiaoyan XU
Chinese Journal of Medical Education Research 2006;0(10):-
This paper aimed at exploring for a scientific method of clinical skill strength-ening training by comparison and analysis on the training examination results of 121 clinical students in Clinical College,Wuhan University of Science and Technology before practice.It was found that the examination achievements of check-up is the lowest in the whole items as a re-sult of lack of normative and precise operation,and style of study is a primary reason to impact class average achievements.Relevant measures are put forward.The study results are available to improve clinic teaching quality.